Get the Stockscreener App
3.52
4.14%
0.14
After Hours:
3.51
-0.01
-0.28%
Anteris Technologies Global Corp stock is traded at $3.52, with a volume of 113.96K.
It is up +4.14% in the last 24 hours and down -44.57% over the past month.
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.
See More
Previous Close:
$3.38
Open:
$3.37
24h Volume:
113.96K
Relative Volume:
0.60
Market Cap:
$145.02M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-1.7792
EPS:
-1.9784
Net Cash Flow:
-
1W Performance:
-4.61%
1M Performance:
-44.57%
6M Performance:
-1.12%
1Y Performance:
+0.00%
1-Day Range:
$3.30
$3.56
1-Week Range:
$3.30
$3.74
52-Week Range:
$2.34
$8.79
Anteris Technologies Global Corp Stock (AVR) Company Profile
Name
Anteris Technologies Global Corp
Sector
Industry
Phone
651-493-0606
Address
860 BLUE GENTIAN ROAD, EAGAN
Compare AVR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
3.52 | 139.25M | 0 | 0 | 0 | -1.9784 |
|
ISRG
Intuitive Surgical Inc
|
561.61 | 195.76B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
192.72 | 54.34B | 21.84B | 1.68B | 2.67B | 5.8322 |
|
ALC
Alcon Inc
|
76.61 | 36.86B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
250.75 | 35.60B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
271.07 | 18.54B | 2.96B | 487.70M | 344.00M | 6.6758 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Lake Street | Buy |
| Jan-07-25 | Initiated | Barclays | Overweight |
| Jan-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
Anteris Technologies Global Corp Stock (AVR) Latest News
Investors in Anteris Technologies Global (ASX:AVR) have unfortunately lost 75% over the last three years - Yahoo Finance
What machine learning models say about Anteris Technologies Global Corp.July 2025 Setups & Daily Stock Trend Watchlist - newser.com
Will Anteris Technologies Global Corp. see short term momentum2025 Institutional Moves & Weekly High Potential Alerts - newser.com
Can Anteris Technologies Global Corp. hit a new high this monthWeekly Trade Report & Real-Time Buy Zone Alerts - newser.com
Published on: 2025-11-19 06:30:50 - newser.com
Is Anteris Technologies Global Corp. stock oversold or undervalued2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com
Will Anteris Technologies Global Corp. continue its uptrendWeekly Profit Summary & Real-Time Buy Signal Alerts - newser.com
Anteris Technologies Global Corp. stock momentum explainedJuly 2025 Final Week & Risk Managed Investment Signals - newser.com
Why Anteris Technologies Global Corp. stock is seen as undervaluedDollar Strength & Growth Focused Investment Plans - newser.com
Promising Potential of Anteris Technologies’ DurAVR System Justifies Buy Rating - TipRanks
Anteris Technologies Reports Positive DurAVR® THV Outcomes - TipRanks
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves - The Manila Times
Anteris (NASDAQ: AVR) Posts 30-Day DurAVR THV Results in 100 Small Annulus Patients - Stock Titan
Detecting price anomalies in Anteris Technologies Global Corp. with AI2025 Price Targets & Safe Entry Trade Signal Reports - newser.com
Anteris Technologies Advances with Stockholder Approvals and PARADIGM Trial Update - MSN
Anteris unveils strong 30-day DurAVR® data in 100-patient small-annulus cohort - Proactive financial news
Anteris Technologies Reports Positive 30-Day Outcomes for DurAVR® THV - TipRanks
Can machine learning forecast Anteris Technologies Global Corp. recoveryJuly 2025 Opening Moves & Expert Curated Trade Setups - newser.com
Analyzing Anteris Technologies Global Corp. with multi timeframe charts2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
Using data models to predict Anteris Technologies Global Corp. stock movementQuarterly Market Review & Stepwise Trade Execution Plans - newser.com
Is Anteris Technologies Global Corp. stock a safe buy before earningsJuly 2025 Market Mood & Technical Pattern Recognition Alerts - newser.com
Using flow based indicators on Anteris Technologies Global Corp.Trade Performance Summary & AI Powered Buy/Sell Recommendations - newser.com
Sio Capital Management, LLC Reduces Stake in Anteris Technologies Global Corp - GuruFocus
What analysts say about Anteris Technologies Global Corp stockStock Watchlist Updates & Chat With Other Investors on Daily Signals - earlytimes.in
Is it time to cut losses on Anteris Technologies Global Corp.Trade Exit Report & Technical Entry and Exit Alerts - newser.com
Anteris Technologies Advances PARADIGM Trial with Regulatory Approvals - TipRanks
Anteris Technologies Reports Q3 2025 Financial Results and Strategic Investments - TipRanks
Danish Regulators Approve Anteris Technologies’ PARADIGM Trial - Medical Product Outsourcing
Anteris Announces Results for the Third Quarter of 2025 - The Manila Times
Anteris Announces Results for the Third Quarter of 2025 - GlobeNewswire Inc.
Australian medtech Anteris stock slides 8% after $89M IPO - MSN
Anteris Technologies Global Corp Stock (AVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):